Cite
Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
MLA
Cruz-Lim, E. M., et al. “Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-Based SABR-5 Phase II Trial.” Clinical Oncology, vol. 36, no. 3, Mar. 2024, pp. 148–56. EBSCOhost, https://doi.org/10.1016/j.clon.2023.11.041.
APA
Cruz-Lim, E. M., Mou, B., Baker, S., Arbour, G., Stefanyk, K., Jiang, W., Liu, M., Bergman, A., Schellenberg, D., Alexander, A., Berrang, T., Bang, A., Chng, N., Matthews, Q., Carolan, H., Hsu, F., Miller, S., Atrchian, S., Chan, E., & Ho, C. (2024). Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial. Clinical Oncology, 36(3), 148–156. https://doi.org/10.1016/j.clon.2023.11.041
Chicago
Cruz-Lim, E.M., B. Mou, S. Baker, G. Arbour, K. Stefanyk, W. Jiang, M. Liu, et al. 2024. “Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-Based SABR-5 Phase II Trial.” Clinical Oncology 36 (3): 148–56. doi:10.1016/j.clon.2023.11.041.